Effects of SGLT2 Inhibitors in Rodent Models of Diabetic Nephropathy. (PubMed, Handb Exp Pharmacol) - Sep 26, 2026 - "Clinical outcome studies have established sodium glucose transporter 2 (SGLT2) inhibitors such as canagliflozin, dapagliflozin, and empagliflozin as nephroprotective agents in diabetic patients. Improvements in female animals tended to be weaker or absent for parameters that were consistently improved in male rodents. Whether this is a peculiarity of the rodent studies or a similar situation exists in diabetic patients remains to be tested."
Journal • Preclinical • Diabetes • Diabetic Nephropathy • Fibrosis • Glomerulonephritis • Immunology • Metabolic Disorders • Nephrology • Renal Disease • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus
|
|
Andrea Pautz; Aqsa Ashfaq; Ebru Arioglu-Inan; Martin C Michel
|